natgillin/translations-raw huggingface dataset:
The 50 mg vial contains an overfill to allow the withdrawal of 50 mg when reconstituted if following the directions described below.
50 mg viala vsebuje presežek za zagotovitev odvzema 50 mg pri rekonstituciji, če se sledi spodnjim navodilom.
The 50 ml syringe containing the diluted Removab solution for infusion is installed in the precision pump.
Namestite 50 ml brizgo, ki vsebuje razredčeno raztopino zdravila Removab za infundiranje, v natančno črpalko.
The 50 ml syringe is closed with a cap and shaken gently to mix the solution.
50 ml brizgo zaprite s pokrovom in zmešajte raztopino z nežnim pretresanjem.
The 50 ml syringe is inserted in the infusion pump.
50 ml brizgo vstavite v črpalko za infundiranje.
The 50 patients who achieved a clinical response after a 12-week open-label run-in were randomized to Kineret (25 patients) or placebo (25 patients), administered daily for an additional 16 weeks.
50 bolnikom, ki so dosegli klinični odziv po 12-tedenskem odprtem poteku, je bilo naključno razdeljeno zdravilo Kineret (25 bolnikov) ali placebo (25 bolnikov), ki so ga dnevno dobivali še nadaljnjih 16 tednov.
The 50% inhibitory concentration (IC50) of amprenavir ranged from 0.012 to 0.08 M in acutely infected cells and was 0.41 M in chronically infected cells (1 M = 0.50 g/ml).
Pri akutno okuženih celicah se je 50 % inhibitorna koncentracija (IC50) amprenavirja gibala med 0,012 in 0,08 M, pri kronično okuženih celicah pa je bila 0,41 M; (1 M = 0,50 g/ml).
The 50% primary generalised tonic-clonic seizures responder rate during the Maintenance Period was significantly higher in the perampanel group (58.0%) than in the placebo group (35.8%),
50 % stopnja odziva pri primarnih generaliziranih napadih s tonično-kloničnimi krči v obdobju vzdrževanja je bila značilno višja v skupini s perampanelom (58,0 %) kot v skupini s placebom (35,8 %), P = 0,0059.
The 500 mg film-coated tablets are yellow, oval and scored on one side.
500 mg filmsko obložene tablete so rumene, podolgovate, z zarezo na eni strani.
The 500 ml vials must not be used for pigs and sheep.
500 ml viale se ne smejo uporabljati za zdravljenje prašičev in ovac.
The 56 x 1 tablet pack is available as perforated unit dose PVC/PVDC blisters sealed with an aluminium foil, all other packs are available with standard PVC/PVDC blisters sealed with an aluminium foil.
Pakiranje 56 x 1 tableta je na voljo v PVC/PVDC perforiranih pretisnih omotih za enkratni odmerek, pokritih z aluminijasto folijo, druga pakiranja pa v standardnih PVC/PVDC pretisnih omotih, pokritih z aluminijasto folijo.
The 5’-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50 - 80 % of the administered dose eliminated by renal excretion.
Zidovudin 5'-glukuronid je glavni presnovek zidovudina v plazmi in v urinu, nanj odpade približno 50 – 80 % apliciranega odmerka, ki se izloči preko ledvic.
The 5’-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50–80% of the administered dose eliminated by renal excretion.
Zidovudin 5'-glukuronid je glavni presnovek zidovudina v plazmi in v urinu, nanj odpade približno 50 – 80 % apliciranega odmerka, ki se izloči preko ledvic.
The 6 month event-free survival for the ITT
Šestmesečno preživetje brez sopojavov v populaciji, ki so jo želeli zdraviti (ITT – »intent-to-treat), je bilo 44 %.
The 6 month treatment duration in this trial was better tolerated than one year of treatment in the pivotal combination trial; for discontinuation 5 % vs.
Bolniki so v tem ključnem kombiniranem preskušanju bolje prenašali 6-mesečno terapijo kot enoletno terapijo; zdravljenje so prekinili pri 5 % oz.
The 6 patients below 6 years were investigated through a single dose pharmacokinetic phase 3b trial (F13CD-3760) and then, included in the on-going long-term follow-up trial (F13CD-3835) assessing the safety and the efficacy of monthly replacement therapy with NovoThirteen.
Šest bolnikov, mlajših od 6 let, so preučili v farmakokinetičnem preskušanju faze 3b s posameznim odmerkom (F13CD-3760) in so jih nato vključili v potekajočo dolgoročno spremljevalno preskušanje (F13CD-3835), ki ocenjuje varnost in učinkovitost mesečnega nadomestnega zdravljenja z zdravilom NovoThirteen.
The 6-month event-free survival for the ITT population was 44 % with a median event-free survival of 4.6 months, which was similar to the results for the progression-free survival.
Šestmesečno preživetje brez dogodkov je bilo za populacijo z namenom zdravljenja 44-odstotno, s srednjim preživetjem brez dogodkov 4,6 meseca, kar je podobno rezultatom za preživetje brez napredovanja bolezni.
The 60 mg capsules are blue and green and are printed with ‘60 mg’ and the code ‘9542’.
60 mg kapsule imajo modra in zelena z vtisnjenim napisom ‘60 mg’ oznako ‘9542’.
The 60 mg capsules are blue and green and are printed with ‘60 mg’ and the code ‘9542’.
60 mg kapsule so modre in zelene z napisom ‘60 mg’ in oznako ‘9542’.
The 60 mg capsules has an opaque green body, imprinted with ‘60 mg’ and an opaque blue cap, imprinted with ‘9542’.
60 mg kapsule imajo neprozorna zelena telesa z vtisnjenim napisom ‘60 mg’ in neprozorne modre pokrovčke z vtisnjenim napisom ‘9542’.
The 60 mg capsules have an opaque blue cap and opaque yellow body, imprinted in white ink with ‘MYLAN’ over ‘DL 60’ on both the cap and the body.
60 mg kapsule imajo rumeno neprozorno telo in moder neprozoren pokrovček ter z belim črnilom vtisnjeno oznako ‘MYLAN’ preko 'DL 60' na pokrovčku in telesu kapsule.
The 600 mg dose should be administered as a subcutaneous injection every three weeks.
600-mg odmerek je treba aplicirati s subkutano injekcijo vsake tri tedne.
The 600 mg dose should be administered as a subcutaneous injection only over 2-5 minutes every three weeks.
Odmerek 600 mg moramo dati izključno s subkutano injekcijo v 2 do 5 minutah vsake tri tedne.
The 600-mg dose was as effective as the 400-mg dose, but it had more side effects.
600-miligramski odmerek je bil učinkovitejši od 400-miligramskega, vendar je povzročal več neželenih učinkov.
The 63 enrolled patients had a median age of 51 years (range 24 to 68 years; with 2% above 65 years); 54% were male; 43% had a BMI ≥ 30 kg/m2; the median baseline HCV RNA level was 6.01 log10 IU/ml; 37% had cirrhosis; 30% had HCV genotype 4a, and 56% HCV genotype 4c or 4d; 79% had non-CC IL28B alleles (CT or TT); 52% were treatment-naïve, and 48% were treatment-experienced.
63 vključenih bolnikov je imelo mediano starost 51 let (razpon 24 do 68 let; z 2% starejših od 65 let); 54% je bilo moških; 43% je imelo ITM ≥ 30 kg/m2; mediana izhodiščne koncentracije HCV RNK je bila 6,01 log10 i.e./ml; 37% jih je imelo cirozo; 30% je bilo okuženih s HCV genotipa 4a, in 56% okužbo s HCV genotipa 4c ali 4d; 79% jih je imelo ne-CC IL28B alele (CT ali TT); 52% bolnikov še ni bilo zdravljenih, in 48% bolnikov je že bilo zdravljenih.
The 64Cu gamma dose constant is 3.6 x 10-5 mSv x MBq-1 x h at a distance of 1 meter.
Na razdalji 1 metra je konstanta bakrovega (64Cu) odmerka gama 3,6 x 10-5 mSv x MBq-1 x h.
The 6–mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions.
Presnovki 6-merkaptopurina zavirajo de novo sintezo purina in interkonverzijo purinskih nukleotidov.
The 7.5 ml dosing syringe has graduations from 0.8 ml to 7.5 ml.
Odmerna brizga z oznako 7,5 ml ima oznako od 0,8 ml do 7,5 ml.
The 74 enrolled patients had a median age of 56 years (range: 43 to 68 years); 91.9% of the patients were male; 24.3% had a body mass index ≥ 30 kg/m2; 1.4% were Black; 95.9% had baseline HCV RNA levels ≥ 800,000 IU/ml; 10.8% had bridging fibrosis; none had cirrhosis; 38.9% had HCV genotype 1a; 58.3% had HCV genotype 1b; 2.8% had HCV genotype 1d; 21.6% had IL28B genotype CC; 54.1% had IL28B genotype CT; 24.3% had IL28B genotype TT; 28.4% (n = 21) were HCV treatment- naïve; 71.6% (n = 53) were treatment-experienced [14.9% (n = 11) were prior relapsers; 40.5% (n = 30) were prior non-responders; 16.2% (n = 12) could not be classified]; median time since liver transplantation was 2.5 years (range: 0.6 to 9.5 years); 67.6% (n = 50) received tacrolimus; 32.4% (n = 24) received cyclosporine A.
Vključenih je bilo 74 bolnikov, mediana starost je bila 56 let (razpon: 43-68 let); 91,9% je bilo moških; 24,3% je imelo indeks telesne mase ≥ 30 kg/m2; 1,4% je bilo črncev; 95,9% je imelo začetne koncentracije HCV RNK ≥ 800.000 i.e./ml; 10,8% je imelo mostno fibrozo; nihče ni imel ciroze; 38,9% je imelo HCV genotip 1a; 58,3% je imelo HCV genotip 1b; 2,8% je imelo HCV genotip 1d; 21,6% je imelo IL28B genotip CC; 54,1% je imelo IL28B genotip CT; 24,3% je imelo IL28B genotip TT; 28,4% (n = 21) še ni prejemalo zdravil proti HCV; 71,6% (n = 53) se je že zdravilo proti HCV [pri 14,9% (n = 11) se je bolezen po predhodnjem zdravljenju ponovila; pri 40,5% (n = 30) ni bilo odziva na predhodnje zdravljenje; pri 16,2% (n = 12) odziva niso mogli opredeliti]; mediani čas od presaditve jeter je bil 2,5 let (razpon: 0,6-9,5 let); 67,6% (n = 50) je prejemalo takrolimus; 32,4% (n = 24) je prejemalo ciklosporin A.
The 740 enrolled patients had a median age of 51 years (range: 18 to 70); 60% of the patients were male; 21% had a body mass index ≥ 30 kg/m2; 5% were Black; 2% were Asian; 85% had baseline HCV RNA levels ≥ 800,000 IU/ml; 15% had bridging fibrosis; 14% had cirrhosis; 57% had HCV genotype 1a; and 43% had HCV genotype 1b.
Vključenih je bilo 740 bolnikov, mediana vrednost starosti je bila 51 let (razpon od 18 do 70), od tega je bilo 60% moških, 21% je imelo indeks telesne mase ≥ 30 kg/m2, 5% je bilo črncev, 2% azijcev, 85% je imelo začetno koncentracijo HCV RNK ≥ 800.000 i.e./ml, 15% je imelo mostno fibrozo, 14% je imelo cirozo, 57% je imelo HCV genotip 1a in 43% je imelo HCV genotip 1b.
The 75 mg hard capsule consists of a grey opaque body bearing the imprint “ROCHE” and a light yellow opaque cap bearing the imprint “75 mg”.
75-mg trda kapsula ima sivo neprozorno telo z napisom “ROCHE” in svetlo rumen neprozoren pokrov z napisom “75 mg”.
The 750 mg film-coated tablets are light red, oblong and scored on both sides.
750 mg filmsko obložene tablete so svetlo rdeče, podolgovate, z zarezo na obeh straneh.
The 8 mg pre-filled syringe presentation of Relistor should only be used to treat these patients when existing medical conditions require the dose to be decreased to 8 mg (0.4 mL of solution), see Special Populations.
Zdravilo Relistor v obliki 8-mg napolnjene injekcijske igle je treba pri teh bolnikih uporabljati samo, če je treba zaradi obstoječih zdravstvenih težav odmerek zmanjšati na 8 mg (0,4 ml raztopine), glejte Posebne skupine bolnikov.
The 8 mg tablets are blue, oval, biconvex, film-coated, and engraved on one side with the letters ‘FT’.
8 mg tablete so modre, ovalne, bikonveksne, filmsko obložene in imajo na eni strani vtisnjeno oznako “FT”.
The 80 mg capsules also contain red iron oxide (E172)
80 mg kapsule vsebujejo tudi rdeč železov oksid (E172)
The 80 mg film-coated tablets are marked on one side with ‘80’.
80 mg filmsko obložene tablete imajo na eni strani vtisnjeno oznako ‘80’.
The 80/25 mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5 mg tablets or who have been stabilised using the two active substances taken separately before switching to Actelsar HCT.
Tablete po 80/25 mg se dajejo bolnikom, pri katerih se krvni tlak ne uravna z jemanjem tablet po 80/12,5 mg ali pri katerih se je krvni tlak stabiliziral z uporabo dveh zdravilnih učinkovin, ki so ju jemali ločeno, preden so prešli na zdravilo Actelsar HCT.
The 80/25 mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5 mg tablets or who have been stabilised using the two active substances taken separately before switching to Kinzalkomb.
Tablete v odmerku 80 mg/25 mg se dajejo bolnikom, pri katerih krvnega tlaka ni mogoče uravnati z jemanjem tablet v odmerku 80 mg/12,5 mg ali pri katerih se je krvni tlak stabiliziral z uporabo dveh zdravilnih učinkovin, ki so ju jemali ločeno, preden so prešli na zdravilo Kinzalkomb.
The 80/25 mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5 mg tablets or who have been stabilised using the two active substances taken separately before switching to PritorPlus.
Tablete v odmerku 80 mg/25 mg se dajejo bolnikom, pri katerih krvnega tlaka ni mogoče uravnati z jemanjem tablet v odmerku 80 mg/12,5 mg ali pri katerih se je krvni tlak stabiliziral z uporabo dveh zdravilnih učinkovin, ki so ju jemali ločeno, preden so prešli na zdravilo PritorPlus.
The 80/25 mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5 mg tablets or who have been stabilised using the two active substances taken separately before switching to Tolucombi.
Tablete po 80/25 mg se dajejo bolnikom, pri katerih se krvni tlak ne uravna z jemanjem tablet po 80/12,5 mg ali pri katerih se je krvni tlak stabiliziral z uporabo dveh zdravilnih učinkovin, ki so ju jemali ločeno, preden so prešli na zdravilo Tolucombi.
The 95% confidence interval is stated in ‘[]’
95-% interval zaupanja je naveden v “[]”.
The [90Y]-radiolabelled Zevalin solution must be prepared according to section 12.
Z [90Y] označeno raztopino zdravila Zevalin morate pripraviti v skladu z navodili v poglavju 12.
The ABASAGLAR cartridges are to be used only in conjunction with a reusable pen recommended for the use with Lilly insulin cartridges (see section 4.4).
Vložke ABASAGLAR lahko uporabljate samo skupaj z injekcijskim peresnikom za večkratno uporabo, ki je priporočen za uporabo z insulinskimi vložki Lilly (glejte poglavje 4.4).
The ABASAGLAR cartridges are to be used only in pens recommended for Lilly insulin cartridges to ensure you get the correct dose.
Da boste zagotovo prejeli pravilen odmerek, vložke ABASAGLAR uporabljajte le v peresnikih, ki so priporočeni za uporabo z insulinskimi vložki Lilly.
The ABASAGLAR dose regimen (dose and timing) should be individually adjusted.
Odmerjanje (odmerek in čas apliciranja) zdravila ABASAGLAR mora biti prilagojeno individualno.
the abdomen (except for the area around the navel)
trebuh (razen predela okrog popka)
The ability of Bexsero to trigger the production of antibodies (immunogenicity) has been assessed in two main studies.
Učinkovitost cepiva Bexsero pri sprožanju nastanka protiteles (imunogenosti) so ocenjevali v dveh glavnih študijah.
The ability of Cetrotide to prevent premature ovulation has been studied in three main studies involving 814 women.
Sposobnost zdravila Cetrotide za preprečitev prezgodnje ovulacije so proučevali v treh glavnih študijah, v katere je bilo vključenih 814 žensk.
The ability of dogs to sire offspring following their return to normal plasma testosterone levels, after the administration of the veterinary medicinal product, has not been investigated.
Sposobnosti psov, da zaplodijo potomstvo, potem ko se jim po uporabi zdravila plazemska koncentracija testosterona vrne na normalno vrednost, niso raziskovali.
The ability of Nimenrix to trigger the production of antibodies (immunogenicity) was assessed in five main studies involving over 4,000 participants.
Učinkovitost cepiva Nimenrix pri sprožanju nastanka protiteles (imunogenosti) so ocenjevali v petih glavnih študijah, v katerih je sodelovalo več kot 4 000 oseb.
The ability of Synflorix to trigger the production of antibodies (immunogenicity) was assessed in one main study involving 1,650 healthy infants aged between six and 12 weeks.
Sposobnost cepiva Synflorix, da spodbudi nastajanje protiteles (imunogenost), je bila ovrednotena v eni glavni študiji, v katero je bilo vključenih 1 650 zdravih dojenčkov, starih od šest do 12 tednov.
The ability to drive and operate machines may be impaired by some adverse reactions associated with HyQvia.
Nekateri neželeni učinki, povezani z zdravilom HyQvia, lahko poslabšajo sposobnost vožnje in upravljanja s stroji.
The ability to drive and operate machines may be impaired by some adverse reactions associated with Privigen.
Nekateri neželeni učinki, povezani z zdravilom Privigen, lahko vplivajo na sposobnost vožnje in upravljanja s stroji.
The ability to drive and operate machines may be impaired by some adverse reactions, such as dizziness, associated with Flebogamma DIF.
Na sposobnost vožnje in upravljanja s stroji lahko vplivajo neželeni učinki, povezani z zdravilom Flebogamma DIF, kot je omotica.
The ability to induce protection against homologous and heterologous vaccine strains was assessed non- clinically using ferret challenge models.
Sposobnost za indukcijo zaščite proti homolognim in heterolognim cepilnim sevom so ocenili predklinično s provokacijskim modelom pri belem dihurju.
The abnormalities are generally of mild to moderate severity, not associated with clinical manifestations, and do not usually require dose interruptions or reductions.
Odstopanja od normalnih vrednosti so običajno majhna do zmerna in niso klinično izražena ter običajno zaradi tega ni treba prekiniti odmerjanja ali zmanjšati odmerka.
The above events were not cumulative, were typically reversible and generally did not result in treatment discontinuation.
Opisani učinki niso bili kumulativni, so bili praviloma reverzibilni in na splošno niso povzročili prekinitve zdravljenja.
The above reactions were not cumulative, were typically reversible and generally did not result in treatment discontinuation.
Opisani učinki niso bili kumulativni, so bili praviloma reverzibilni in na splošno niso povzročili prekinitve zdravljenja.
the absence of a clear aetiology for the lymphadenopathy or in the presence of acute infectious mononucleosis, discontinuation of Protopy should be considered.
V odsotnosti jasne etiologije za limfadenopatijo ali v navzočnosti akutne infekcijske mononukleoze je treba pretehtati opustitev Protopya.
The absence of Capillaria spp infestation should be confirmed prior to use of the product.
Odsotnost infestacij s Capillaria spp. je potrebno potrditi, preden uporabite zdravilo.
The absence of Capillaria spp infestation should be confirmed prior to use of the product.
Odsotnost infestacije s Capillaria spp. je treba potrditi, preden uporabite zdravilo.
the absence of cardioselective beta-1 beta-blocking activity,
odsotnost kardioselektivne beta-1 aktivnosti antagonistov adrenergičnih receptorjev beta,
The absence of pharmacokinetic difference between the 2 formulations was shown in an open- label randomised two-period cross-over study in 24 adult healthy volunteers.
Odprta randomizirana navzkrižna študija z dvema periodama, v kateri je sodelovalo 24 odraslih zdravih prostovoljcev, je pokazala odsotnost farmakokinetičnih razlik med omenjenima dvema oblikama.
The absolute bioavailability (70%) of insulin glulisine was similar between injection sites and of low intra-subject variability (11%CV).
Absolutna biološka uporabnost (70 %) insulina glulisin je bila med mesti injiciranja podobna in je imela majhno intraindividualno variabilnost (11 % KV).
The absolute bioavailability (AUC) for a single oral 150 mg migalastat hydrochloride dose or a single 2-hour 150 mg intravenous infusion was approximately 75%.
Absolutna biološka uporabnost (AUC) enkratnega peroralnega odmerka 150 mg migalastat hidroklorida ali enkratne dveurne 150-mg intravenske infuzije je bila približno 75 %.
The absolute bioavailability after oral administration was found to be 33 %.
Ugotovili so, da je absolutna biološka razpoložljivost po peroralnem dajanju 33 %.
The absolute bioavailability after SC dosing was determined to be 72% from pharmacokinetic models.
Na podlagi farmakokinetičnih modelov je absolutna biološka uporabnost po subkutanem odmerjanju 72 %.
The absolute bioavailability increased from 29% at a dose of 25 mg to 35% at a dose of 50 mg.
Absolutna biološka uporabnost se je povečala z 29 % pri odmerku 25 mg na 35 % pri odmerku 50 mg.
The absolute bioavailability is 58% (48-70%1).
Njegova absolutna biološka uporabnost je 58 % (od 48 do 70 %1).
The absolute bioavailability is 81% and 65% for the A3 and A4 forms, respectively.
Absolutna biorazpoložljivost je 81% in 65% za A3 in A4 obliki.
The absolute bioavailability is approximately 32 %.
Absolutna biološka uporabnost je približno 32%.
The absolute bioavailability of 100 micrograms of parathyroid hormone after subcutaneous administration in the abdomen is 55.
Absolutna biološka dostopnost 100 g obščitničnega hormona po podkožnem dajanju v trebuh je 55%.
The absolute bioavailability of a 100 mg dose is 23% and is predicted to be 33% at 300 mg.
Absolutna biološka uporabnost 100 mg odmerka je 23 % in predvidoma 33 % pri 300 mg.
The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg.
Pri odmerkih do 10 mg je absolutna biološka uporabnost apiksabana približno 50 %.
The absolute bioavailability of bazedoxifene is approximately 6%.
Absolutna biološka uporabnost bazedoksifena je približno 6 %.
The absolute bioavailability of betaine anhydrous has not been determined.
Absolutne biološke uporabnosti brezvodnega betaina niso ugotovili.
The absolute bioavailability of cetrorelix after subcutaneous administration is about 85%.
Absolutna biološka uporabnost cetroreliksa po subkutani uporabi je približno 85 %.
The absolute bioavailability of dabigatran following oral administration of Pradaxa was approximately 6.5 %.
Absolutna biološka uporabnost dabigatrana je bila po peroralni aplikaciji zdravila Pradaxa približno 6,5 %.
The absolute bioavailability of emtricitabine from Emtriva 200 mg hard capsules was estimated to be 93% and the absolute bioavailability from Emtriva 10 mg/ml oral solution was estimated to be 75%.
Ocenjena absolutna biološka uporabnost emtricitabina, uporabljenega v obliki Emtriva 200 mg trde kapsule, je 93 % in ocenjena absolutna vrednost biološke uporabnosti emtricitabina, uporabljenega v obliki Emtriva 10 mg/ml peroralne raztopine, je 75 %.
The absolute bioavailability of enoxaparin after subcutaneous injection, based on anti-Xa activity, is approximately 100%.
Po subkutanem injiciranju je absolutna biološka uporabnost enoksaparina, določena na podlagi aktivnosti Xa, skoraj 100-odstotna.
The absolute bioavailability of inhaled umeclidinium was on average 13% of the dose, with negligible contribution from oral absorption.
Absolutna biološka uporabnost inhaliranega umeklidinijevega bromida je bila v povprečju 13 % odmerka; prispevek peroralne absorpcije je bil zanemarljiv.
The absolute bioavailability of Instanyl is about 89.
Absolutna biološka uporabnost zdravila Instanyl znaša približno 89 %.
The absolute bioavailability of insulin detemir when administered subcutaneous is approximately 60%.
Absolutna biološka uporabnost insulina detemir znaša pri subkutani aplikaciji približno 60 %.
The absolute bioavailability of oral abacavir and lamivudine in adults is about 83% and 80-85% respectively.
Pri odraslih znaša absolutna biološka razpoložljivost abakavirja in lamivudina po peroralnem dajanju približno 83% oziroma 80 – 85%.
The absolute bioavailability of oral abacavir and lamivudine in adults is about 83% and 80-85% respectively.
Pri odraslih znaša absolutna biološka uporabnost peroralno danega abakavirja približno 83 %, peroralno danega lamivudina pa približno 80–85 %.
The absolute bioavailability of oral abacavir, lamivudine and zidovudine in adults is about 83 %, 80 - 85 % and 60 - 70 % respectively.
Pri odraslih znaša absolutna biološka uporabnost peroralnega abakavirja približno 83 %, peroralnega lamivudina približno 80 – 85 % in peroralnega zidovudina približno 60 – 70 %.
The absolute bioavailability of sitagliptin is approximately 87 %.
Absolutna biološka uporabnost sitagliptina je približno 87 %.
The absolute bioavailability of subcutaneous injectable epoetin alfa is approximately 20% in healthy subjects.
Absolutna biološka uporabnost subkutano injiciranega epoetina alfa pri zdravih osebah je približno 20 %.
The absolute bioavailability of subcutaneously administered interferon beta-1b was approximately 50%.
Absolutna biološka uporabnost subkutano uporabljenega interferona beta-1b je bila 50 %.
The absolute bioavailability of TAGRISSO has not been determined.
Absolutna biološka uporabnost zdravila TAGRISSO ni ugotovljena.